skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

Refine Results

Clear All


Show More


Show More

Show More


Show More

Show More

9 Total results for product and free and sample content found

Generics Bulletin

Biocon’s Malaysia Insulin Facility Hit With 12 FDA Observations

By Penelope MacRae 12 Jul 2019

The US FDA has slapped Biocon with a dozen observations over three units at its insulin manufacturing facility in Malaysia, but the Indian biotech firm says the problems can be remedied quickly and that US launch plans are on track for its insulin product glargine challenging French drug-maker Sanofi’s multi-billion-dollar Lantus.

Topic FDA Diabetes BioPharmaceutical


Hanmi Faces Another Licensee U-Turn, This Time Janssen On Obesity/Diabetes Drug

By Jung Won Shin 05 Jul 2019

Janssen has returned the rights to an obesity/diabetes drug to originator Hanmi, after Phase II studies failed to achieve glycemic control targets and reflecting development difficulties in the sector. This is the fourth time for the Korean firm to face a U-turn of licensed out compounds. 

Topic Diabetes Obesity

Medtech Insight

UK Plan To Speed Access To ‘Cutting-Edge’ Products

By Ian Schofield 03 Jul 2019

Changes are being made to the UK’s Accelerated Access Collaborative to help streamline access to ground-breaking medicines and diagnostic tools in areas like dementia, diabetes and cancer.

Topic Business strategies Cancer Diabetes

Pink Sheet

Insulin Prices: House Hearing Displays Bipartisan Commitment To Rapid Reform

By Cathy Kelly 02 Jul 2019

Reform "is going to happen,” promised Energy & Commerce Oversight Subcommittee Chair Diana DeGette, suggesting the panel’s next hearing on insulin price reform may be held in July.

Topic Diabetes

Datamonitor Healthcare

Pharma Diabetes Market Intelligence

10 Apr 2019

These reports includes 20-year forecasts of prevalent type 1 and type 2 diabetes cases segmented by age and gender, and drug-treated diabetes, segmented by treatment type.

Topic Diabetes


ADA Meeting's Around The Corner: Five Things To Watch For

By Emily Hayes 21 Jun 2018

Among other debates at the American Diabetes Association annual meeting, clinicians will discuss the future of cardiovascular outcomes studies for diabetes drugs – whether they should maintain course or are due for an overhaul.

Topic Diabetes

Datamonitor Healthcare

Future market dynamics in type 2 diabetes

13 Sep 2017

With the type two diabetes market undergoing unprecedented changes its important to know how this will shape the future dynamics of this competitive market. With our coverage you're able to analyse every aspect of this market.

Topic Diabetes

Medtech Insight

Start-Up Spotlight: Origin Inc., Healing Diabetic Foot Ulcers

By Catherine Longworth 04 Apr 2017

Nitric oxide plasma technology from US start-up Origin, Inc could hold the key to wound healing for patients suffering from chronic diabetic foot ulcers. Based on Nobel prize winning research, the privately-held company has developed a handheld, computer-guided system that generates NO from ambient room air within a defined plasma stream.

Topic Diabetes

Datamonitor Healthcare

EMPA-REG OUTCOME: Jardiance set for boost in uptake as it raises the bar in type 2 diabetes

By Rajan Sharma 21 Sep 2015

The sodium-glucose cotransporter-2 (SGLT-2) inhibitor Jardiance (empagliflozin; Boehringer Ingelheim/Eli Lilly) is expected to experience a significant increase in uptake in the type 2 diabetes market after the presentation of its much-anticipated cardiovascular (CV) outcomes data at the 51st European Association for the Study of Diabetes Annual Meeting in Stockholm, Sweden.

Topic Diabetes

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: